TCL Archive In Brief: ASCO Letter To Clinton Urges support For Trials; Senator Praises NCI, Bristol; Berlin Back A NCI January 15, 1993
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
